A new trading day began on Friday, with Astria Therapeutics Inc (NASDAQ: ATXS) stock price down -3.23% from the previous day of trading, before settling in for the closing price of $7.75. ATXS’s price has ranged from $6.95 to $16.90 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 29.91%. With a float of $45.38 million, this company’s outstanding shares have now reached $56.43 million.
Let’s look at the performance matrix of the company that is accounted for 59 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Astria Therapeutics Inc (ATXS) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Astria Therapeutics Inc is 19.58%, while institutional ownership is 87.24%. The most recent insider transaction that took place on Apr 01 ’24, was worth 135,939. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $13.59, taking the stock ownership to the 0 shares. Before that another transaction happened on Feb 01 ’24, when Company’s Director bought 2,481,350 for $12.09, making the entire transaction worth $29,999,522. This insider now owns 4,873,721 shares in total.
Astria Therapeutics Inc (ATXS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.91% per share during the next fiscal year.
Astria Therapeutics Inc (NASDAQ: ATXS) Trading Performance Indicators
Here are Astria Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.09, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.78 in one year’s time.
Technical Analysis of Astria Therapeutics Inc (ATXS)
Astria Therapeutics Inc (NASDAQ: ATXS) saw its 5-day average volume 0.44 million, a positive change from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 26.54%. Additionally, its Average True Range was 0.49.
During the past 100 days, Astria Therapeutics Inc’s (ATXS) raw stochastic average was set at 5.90%, which indicates a significant decrease from 15.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.67% in the past 14 days, which was lower than the 60.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.63, while its 200-day Moving Average is $10.34. Nevertheless, the first resistance level for the watch stands at $7.78 in the near term. At $8.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.23. If the price goes on to break the first support level at $7.33, it is likely to go to the next support level at $7.17. The third support level lies at $6.88 if the price breaches the second support level.
Astria Therapeutics Inc (NASDAQ: ATXS) Key Stats
With a market capitalization of 423.26 million, the company has a total of 56,434K Shares Outstanding. Currently, annual sales are 0 K while annual income is -72,890 K. The company’s previous quarter sales were 0 K while its latest quarter income was -24,530 K.
